Food & Health
Pipeline Pressures Challenge Novartis Post Avidity Deal
Novartis's Avidity acquisition faces scrutiny after neuromuscular drug trial misses key goals. Explore the implications on deal valuation.
Food & Health
Novartis's Avidity acquisition faces scrutiny after neuromuscular drug trial misses key goals. Explore the implications on deal valuation.